EGFR and cholangiocarcinoma: Of the 11 evaluable patients, 2 patients achieved PR, and 5 had SD.79 In the same trial, CAR T-EGFR treatment was further explored for the treatment of advanced BTC and PC.80–82 For BTC, 19 patients (14 cholangiocarcinomas (CCA) and 5 gallbladder carcinomas) with EGFR-positive (>50%) advanced unresectable, relapsed/metastatic BTC were treated with CAR T-EGFR cells.